Atara Biotherapeutics (ATRA) EBT Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported EBT Margin of 803.29% for Q1 2026, down 84202.0% on a YoY basis from N/an in Q1 2025, and up 64.55% quarter-over-quarter from 2266.02% in Q4 2025.
Atara Biotherapeutics (ATRA) EBT Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported EBT Margin for 5 years, with the latest figure at 803.29% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 84202.0% year-over-year to 803.29%; the trailing twelve-month figure through Mar 2026 stood at 182.26% (down 17441.0% YoY), and the FY2025 full-year result was 0.01%, up 6623.0% from the prior year.
- EBT Margin for Q1 2026 stood at 803.29%, up from 2266.02% in the prior quarter.
- The five-year high for EBT Margin was 38.73% in Q1 2025, with the low at 33789.59% in Q4 2022.
- Historically, EBT Margin has averaged 3621.81% across 5 years, with a median of 463.55% in 2026.
- The largest YoY upside for EBT Margin was 3254497 bps in 2023 against a maximum downside of 900264 bps in 2023.
- Atara Biotherapeutics' EBT Margin stood at 33789.59% in 2022, then surged by 96 bps to 1244.63% in 2023, then jumped by 97 bps to 38.81% in 2024, then sank by 5738 bps to 2266.02% in 2025, then surged by 65 bps to 803.29% in 2026.
- The last three EBT Margin figures came in at 803.29% (Q1 2026), 2266.02% (Q4 2025), and 123.81% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -803.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -2,266.02% |
| Sep 30, 2025 | -123.81% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.81% |
| Sep 30, 2024 | -54.56% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -115.98% |
| Dec 31, 2023 | -1,244.63% |
| Sep 30, 2023 | -3,265.48% |
| Jun 30, 2023 | -8,966.83% |
| Mar 31, 2023 | -6,096.98% |
| Dec 31, 2022 | -33,789.59% |
| Jun 30, 2022 | 35.80% |
| Mar 31, 2022 | -1,204.61% |